ObjectiveTo observe the clinical efficacy of superficial needling in treating senile intractable constipation.Method The recruited patients were randomized into a treatment group and a control group, 40 in each group. The treatment group was intervenedby superficial needling, while the control group was by oral administration of Phenolphthalein tablets. The two groups both received the treatments for 4 weeks.ResultThe therapeutic efficacy increased with the treatment; patients showed improvements indefecation frequency, stool constitution, and effort in defecation (P<0.05); there was a significant difference between the treatment group and the control group (P<0.05); the residual marker counts of 48 h and 72 h after treatment were significantly lowered in both groups compared to that before treatment (P<0.05).ConclusionSuperficial needling can obviously improve the symptoms of senile intractable constipation, promoting the gastrointestinal transit motility.

OBJECTIVE:To refine the quality standard of pharmacy intravenous admixture service(PIVAS),and provide refer-ence for improving the work quality of PIVAS. METHODS:Through establishing quality management organization and developing quality standard rules,quality control system for PIVAS in our hospital was constructed and total quality management was conduct-ed. Numbers of quality problems before(Jul. 2013-Jun. 2014)and after(Jul. 2014-Jun. 2015)its implementation were compared, and the effects were evaluated. RESULTS:117 management systems and 14 link quality standards and rules were made,including staff behavior standards,quality standards for drug management,supervision and inspection of quality standards,etc. Numbers of quality problems dropped from 358 to 177 after the implementation,the ratio of dispensing errors accounted for the total dispensing declined from 0.35? to 0.17?(P<0.05). CONCLUSIONS:The construction of quality control system and the implementation of quality control standards and rules in PIVAS of our hospital has improved the quality of PIVAS work.

OBJECTIVE:To provide reference for standardizing dispensing and use of intravenous drug. METHODS:266 piec-es of intravenous drug instructions were collected in PIVAS of our hospital,and then the labeling information were statistically ana-lyzed,including dispensing method,diluted or dissolved solvent before preparation and storage time after preparation. RESULTS:Among 266 intravenous drug instructions,there were 45 kinds of finished product infusion varieties and 221 kinds of drugs needing to be prepared. Among these,there were only 30 pieces of drug instructions with labeling dispensing method,accounting for 13.57%;195 pieces of drug instructions stated solvent for dilution and 22 stated solvent for dissolution before preparation,account-ing for 88.24% and 19.13%;69 pieces of drug instructions stated storage time,accounting for 31.22%. CONCLUSIONS:The la-bel information of dispensing method and storage time in intravenous drug instructions is markedly insufficient or not clear. Drug ad-ministration departments are suggested to strengthen the instruction standardization management. Meanwhile,manufacturers should specify the relevant information in intravenous drug instructions.

Multiple sclerosis (MS) is a demyelinating autoimmune disease of the central nervous system. It mainly occurs in young and middle-aged people and has a high disability rate. The pathogenesis of MS has not been fully elucidated, with great genetic heterogeneity, diverse clinical phenotypes, lack of specific biomarkers, numerous and complicated research data, which bring great challenges to the diagnosis and treatment of MS. Artificial intelligence (AI), as the cutting-edge hotspot in the development of science and technology, is widely used in the medical field to assist in the diagnosis, treatment and prognosis of various diseases. Its infinite learning ability greatly promotes the management of MS. This article will review the application of AI in MS diagnosis and treatment.

Objective:To systematically review the effects of statins in the treatment of the patients with pneumonia or sepsis, and to provide evidence-based basis for the using of statin in treatment of pneumonia or sepsis.Methods:PubMed, Embase, The Cochrane Library, CNKI, WanFang Data and VIP were searched for randomized placebo-controlled trials of statins published from the establishment time of datebases to January 31, 2015.The qualities of the included studies were independently assessed by two reviewers and the relevant data was extracted for analysis using Review Manager 5.3. Results:Nine trails involving a total of 1 227 patients were included.①A total of 6 studies about the mortality of hospitalized patients were included in the Meta-analysis;compared with placebo group, statins didn’t improve the mortality of hospitalized patients with pneumonia or sepsis;risk ratio (RR)= 0.83,95%CI (0.63,1.08),P=0.17.②A total of 7 studies about the rates of mechanical ventilation usage or ICU admission of the patients were included in the Meta-analysis. Compared with placebo group,statins didn’t improve the rates of mechanical ventilation usage or ICU admission of the patients with bacteria infection;RR= 0.99,95% CI (0.96,1.03),P=0.62.③A total of 4 studies about the levels of C reaction protein (CRP)were included in the Meta-analysis. Compared with placebo group, statins significantly reduced the levels of CRP;mean differences (MD)=-8.30 mg·L-1,95%CI (-12.13,-4.47),P<0.0001. Conclusion:Statins can not significantly reduce both the in-hospital mortality and the rates of mechanical ventilation usage or ICU admission, but can significantly reduce the plasma CRP levels, and reduce the inflammation.

0.05).In SVZ,nNOS expression in ischemic model group was reduced on days 1-14,but increased on day 21;after Ligustrazine administration,nNOS expression was obviously decreased on days 3-14 in all Ligustrazine dose groups,but began to increase on day 21.In CC,nNOS expression in ischemic model group was reduced on days 3-14,and began to increase on day 21;in the different-dose Ligustrazine groups,nNOS expression was significantly decreased on days 3-14,especially in medium-and high-dose groups,but increased on day 21.In striatum and cortex peri-infarction,nNOS expression in ischemic model group was obviously decreased on days 3 and 7,but enhanced on days 14 and 21;in various-dose Ligustrazine groups,nNOS expression was decreased on days 3-21,especially in medium-and high-dose groups,but increased slightly on day 21.In DG and CA1 areas,nNOS expression in ischemic model group was reduced on days 3 and 7,but began to increase on day 14;nNOS expression in all Ligustrazine groups were decreased during 3-21d.There were significant differences between ischemic model group and different-dose Ligustrazine groups at different time points(P

Objective Present study aimed to characterize the alteration of cortical thickness in first-episode, never-medicated, adult patients with major depressive disorder (MDD), and explore whether such deficits were related with their disease duration and clinical symptom severity. Methods Thirty-seven adult MDD patients were recruited from March 2013 to August 2015 as patient group, and 41 healthy volunteers were as control group. All the patients underwent three-dimensional spoiled gradient recalled (3D-SPGR) sequences, and the images were acquired. Constructions of the cortical surface were developed from 3D-SPGR images using FreeSurfer software, and the thickness of the entire cortex was measured according to the automated surface reconstruction, transformation, and high-resolution inter-subject alignment procedures. Finally, cortical thickness was compared between the two groups, and the relativity between clinical symptom severity, disease progression and clinical scores were analyzed using the General Linear Model (GLM). Results Our results revealed a significant increase in cortical thickness(P<0.05, false discovery rate corrected) in the left anterior and middle cingulate cortex, bilateral precentral cortex, left paracentral cortex, bilateral superior parietal cortex, left temporal pole, and right lateral occipital cortex (cortical thickness 1.89-2.87 mm, cortical volume 34-384 mm2, P<0.05) in MDD patients compared to healthy controls, while no reversed alternation was found. In addition, clinical symptom severity and disease progression showed no correlation with the cortical thickness abnormalities in MDD group(P>0.05). Conclusion Excluding the impact of treatment, our study showed that the cortical thickness change was mainly located in the prefrontal-limbic system in the in early course of MDD.

To explore the effects of Yixin Jiedu Formula (YXJDF), a compound Chinese herbal medicine, on hemodynamic and B-type natriuretic (BNP) in a rat model of heart failure with qi deficiency and blood stasis syndrome. Moreover, its therapeutic effects in improving the symptoms were also studied.

Objective The use of sentinel lymph node biopsy (SLNB) following neoadjuvant chemotherapy (NAC) in patients presenting with clinically positive lymph nodes remains controversial.This study is aimed to invest if it is feasible to perform SLNB after NAC in case that axillary lymph nodes turned to clinical negative.Methods A computer-aided search of the literature regarding SLNB in clinically nodepositive breast cancer treated with NAC was carried out to identify the false negative rate (FNR),sentinel lymph node identification rate (IR).Results 16 articles were used in the analysis yielding 1 579 patients.The pooled estimate of FNR,IR,sensitivity and overall accurancy was 13.6％,91％,85.7％,and 92.8％,respectively.Conclusions SLNB after NAC in lymph node-positive patients,whose axillary lymph node was clinical negative after NAC,results in reasonably IR,but FNR was still high to be accepted.More refined patient selection and optimal techniques are expected to lower the FNR in this patient population.

ObjectiveTo investigate the feasibility and isolation efficiency of percutaneous selective isolated hepatic perfusion chemotherapy(PSIHP). MethodsSix pigs underwent the procedure of routine transhepatic arterial infusion(HAI) and 6 underwent PSIHP.5-FU was used in this study. The drug(5-FU) (concentration) of blood from hepatic and systemic veins of both groups was observed. Liver tissue was (investigated) for pathologic changes. ResultsThe peak level of 5-FU concentration in blood from right (hepatic) vein and systemic vein in HAI group was(4082.530415.213)mg/L and (1682.230216.834)mg/L respectively.In PSIHP group, the peak level(5-FU) was(5321.711517.318)mg/L and(510.83452.518)mg/L, respectively.There was a statistically significant difference between HAI group an PSIHP group(P